Skip to main content
OpenTrials
Completed

NCT Number: NCT04097314

Precision Medicine With Zibotentan in Microvascular Angina

Microvascular angina (MVA) is caused by abnormalities of the small vessels in the heart. Endothelin is a small chemical that circulates and accumulates in the blood vessel walls, causing them to narrow or go into spasm and thicken in the longer term especially as levels of endothelin increase. As a result, patients experience pain, psychological burden and an inability to carry out daily activities.

Originally developed by AstraZeneca for cancer treatment, prior research has confirmed that Zibotentan relaxes the small blood vessels of patients with MVA which lends support to the idea that Zibotentan may bring some benefits to patients with MVA. This trial therefore proposes to look into re-purposing zibotentan as a new treatment for patients with MVA. The primary objective is to assess the effect of add-on treatment with Zibotentan to treadmill exercise times in adult patients with MVA and impaired exercise intolerance. Zibotentan could provide a new treatment pathway for patients, as well as be made available to the NHS at substantially lower cost than the currently used medications.

The trial aims to initially invite approx. 356 participants for genetic testing. A minimum of 100 participants will go forward into the main study, receiving either 10mg zibotentan or a dummy matched tablet (placebo) daily over two 12 weeks periods of each, completing their final visit at week 34. The study assessments will involve a health check at each visit, including information on the patient's wellbeing, blood tests, some quality of life questionnaires, and an exercise test. Participants will also have the option to consent to additional sub-study cardiovascular MRI scanning. Finally, participants will be invited to provide consent for long-term follow-up (maximum 20 years) of their electronic medical records (no additional patient contact).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Microvascular Angina Angina Pectoris Cardiovascular Diseases Chest Pain Heart Diseases Myocardial Ischemia Neurologic Manifestations Pain Pathological Conditions, Signs and Symptoms Signs and Symptoms Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

NHS Greater Glasgow and Clyde

Glasgow, United Kingdom

About this study

The study design publication is available at https://pubmed.ncbi.nlm.nih.gov/32942043/

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age >18 years.
  • Microvascular angina - as defined by COVADIS diagnostic criteria for microvascular angina.
  • Able to comply with study procedures.
  • Written informed consent.

Exclusion criteria

  • Exercise tolerance >540 seconds in men and >430 seconds in women (i.e. actual exercise duration (s) achieved on the Bruce protocol commensurate with predicted), or, lack of anginal symptoms and/or ST-segment depression (0.1 mV) limiting exercise.
  • Non-cardiovascular exercise-limiting problem e.g. morbid (or severe) obesity (BMI ≥40.0 kg/m2)
  • Genotype not available
  • Women who are pregnant, breast-feeding or of child-bearing potential (WoCBP) without a negative pregnancy test and who are unwilling or unable to follow the reproductive restrictions and use highly effective contraception as defined in Appendix 3 of the protocol for the duration of the study treatment and 30 days after last dose of study drug.
  • Men who are sexually active with a WoCBP who are unwilling to use condoms or other highly effective methods of contraception for the duration of study treatment and for 14 weeks after last dose of study drug.
  • Heart failure (New York Heart Association Grade ≥II i.e. mild symptoms and slight limitation during ordinary activity)
  • Recent (<3 months) myocardial infarction
  • A history of epilepsy, other CNS adverse events, neurologic symptoms or signs consistent with spinal cord compression or CNS metastases.
  • Moderate or more severe renal impairment (GFR < 45 mL/min)
  • Liver disease with a Child-Pugh score of A (5-6 points) or higher
  • Participation in another intervention study involving a drug within the past 90 days or 5 half-lives whichever is longer (co-enrolment in observational studies is permitted).

Treatment and study plan

Zibotentan

Drug

10mg OD Zibotentan

Placebo oral tablet

Drug

Placebo

Primary outcomes

  1. EFFICACY - Exercise Testing (treadmill exercise time, seconds)

    Time frame: 34 weeks

    The primary outcome is the treadmill exercise time (TET) measured in seconds using the Full Bruce protocol, a measure of aerobic capacity that reflects disease severity. A within-subject improvement in exercise time (tested at week 10 (baseline), week 22 (crossover) and week 34 (final visit)) of 30 seconds is considered clinically relevant.

Secondary outcomes

  1. EFFICACY - Health Status QLQ (Seattle Angina Questionnaire)

    Time frame: 34 weeks

    Seattle Angina Questionnaire (SAQ) Summary Score and component scores (Angina Limitation, Angina Stability, Angina Frequency, Treatment Satisfaction and Quality of Life) will be recorded at all study visits.

  2. EFFICACY - Health Status QLQ (Illness Perception - Brief IPQ)

    Time frame: 34 weeks

    Brief Illness Perception Questionnaire (Brief IPQ), a nine-item scale designed to rapidly assess the cognitive and emotional representations of illness taken at all study visits.

  3. EFFICACY - Health Status QLQ (Anxiety/depression - PHQ4)

    Time frame: 34 weeks

    The Four-Item Patient Health Questionnaire (PHQ-4) for Anxiety and Depression is a validated tool for detecting both anxiety and depressive disorders and will administered at all study visits

  4. EFFICACY - Health Status QLQ (Treatment satisfaction - TSQM)

    Time frame: 34 weeks

    The 14-item Treatment Satisfaction Questionnaire for Medication (TSQM) is a reliable and valid instrument to assess patients' satisfaction with medication, providing scores on four scales - side effects, effectiveness, convenience and global satisfaction and will administered at all study visits

  5. EFFICACY - Health Status QLQ (EQ5D-5L)

    Time frame: 34 weeks

    The 5-item EuroQol Group EQ5D-5L is a validated questionnaire comprising mobility, self-care, usual activities, pain/discomfort and anxiety/depression to quantitatively assess patient's self-reported health status and will be administered at each study visit.

  6. FEASIBILITY - Withdrawal Rate

    Time frame: 34 weeks

    Participant withdrawal rate from study will be measured throughout.

  7. SAFETY - SAEs

    Time frame: 34 weeks

    Number of Participants With Treatment-Related Adverse Events as Assessed and reported by local study teams throughout trial.

  8. EFFICACY - Exercise Testing (time,sec to 1mm ST-depression)

    Time frame: 34 weeks

    Within-subject improvements in time (seconds) to 1 mm ST-depression during exercise tolerance testing will be assessed using the Full Bruce protocol. Assessments will be during screening, week 10 (baseline), week 22 (crossover) and week 34 (final visit).

  9. EFFICACY - Exercise Testing (maximum ST-segment deviation, mV)

    Time frame: 34 weeks

    Within-subject improvements in maximum ST-segment deviation (mV) during exercise tolerance testing will be assessed using the Full Bruce protocol. Assessments will be during screening, week 10 (baseline), week 22 (crossover) and week 34 (final visit).

  10. EFFICACY - Exercise Testing (Time (s) to 75% of max age-related heart rate during exercise)

    Time frame: 34 weeks

    Within-subject improvements in time (seconds) to 75% of max age-related heart rate during exercise tolerance testing will be assessed using the Full Bruce protocol. Assessments will be during screening, week 10 (baseline), week 22 (crossover) and week 34 (final visit).

  11. EFFICACY - Exercise Testing (Metabolic equivalent (METs)

    Time frame: 34 weeks

    Within-subject improvements in metabolic equivalent (METs) during exercise tolerance testing will be assessed using the Full Bruce protocol. Assessments will be during screening, week 10 (baseline), week 22 (crossover) and week 34 (final visit). The resting metabolic rate is defined as 3.5 ml O2/kg/min (METs).

  12. EFFICACY - Exercise Testing (DUKE Score)

    Time frame: 34 weeks

    Within-subject improvements in Duke treadmill score (DTS) during exercise tolerance testing will be assessed using the Full Bruce protocol. Assessments will be during screening, week 10 (baseline), week 22 (crossover) and week 34 (final visit). Duke treadmill score is defined as maximum exercise time in minutes - (5 × the maximal net ST-segment deviation in mm during or after exercise) - (4 × the treadmill angina index (where 0 = no angina, 1 = non-limiting angina, 2 = exercise limiting angina).

Other outcomes

  1. EFFICACY - Pharmacodynamics (Exploratory)

    Time frame: 34 weeks

    Blood samples will be obtained at weeks 10, 22 and 34 to measure circulating concentrations of mechanistic biomarkers. These analyses are intended to provide insights into the mechanisms of treatment-related efficacy and safety responses.These measurements will be considered an exploratory endpoint.

  2. EFFICACY - Pharmacokinetics (Exploratory)

    Time frame: 34 weeks

    Blood samples will be obtained at weeks 10, 22 and 34 to measure steady-state plasma concentrations of zibotentan with a validated assay. These measurements will be considered an exploratory endpoint.

  3. EFFICACY - Angina Diary (Exploratory)

    Time frame: 34 weeks

    A novel, bespoke questionnaire for the diagnostic classification of patients with ischaemia with non-obstructive coronary artery disease (INOCA) and their treatment response will be assessed as an exploratory outcome. Patients are asked to complete this diary every time they suffer angina symptoms over the course of the trial.

Sponsors and collaborators

Lead sponsor

NHS Greater Glasgow and Clyde

Other

Collaborators

  • AstraZeneca
  • Blackpool Teaching Hospitals NHS Foundation Trust
  • King's College London
  • Oxford University Hospitals NHS Trust
  • Papworth Hospital NHS Foundation Trust
  • Royal Free Hospital NHS Foundation Trust
  • Siemens Healthcare Ltd
  • University of Cambridge
  • University of Glasgow
  • University of Oxford

Registry information

Official study title

A Randomised, Double-blind, Placebo-controlled, Cross-over Trial of Zibotentan in Microvascular Angina

Acronym: PRIZE

Important dates

Study start
2019
Primary completion
2023
Study completion
2023
First posted
Sep 20, 2019
Registry last updated
Aug 4, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.